Skip to main content
. 2021 Nov 17;10(22):5359. doi: 10.3390/jcm10225359

Table 2.

Clinical and biochemical parameters of patients with IBD evaluated at the time of the liver pathology diagnosis.

Parameter Patients with Liver Pathology (n = 21)
Type of hepatobiliary manifestation, n (%): IBD (n = 21) CD (n = 7) UC (n = 14)

  • No defined etiology (idiopathic)

 7 (33%) 3 (43%) 4 (29%)

  • PSC

 4 (19%) 0 4 (29%)

  • ASC

 1 (5%) 0 1 (7%)

  • AIH

 1 (5%) 0 1 (7%)

  • NAFLD

 4 (19%) 1 (14%) 3 (21%)

  • Cholelithiasis

 1 (5%) 1 (14%) 0

  • Drug hepatotoxicity

 2 (9%) 1 (14%) 1 (7%)

  • Viral infection

 1 (5%) 1 (14%) 0
IBD activity, median (range), score

  • PCDAI

 NA 5 (2.5–15) NA

  • PUCAI

 NA NA 37.5 (0–70)
IBD activity, n (%)

  • Remission

 9 (43%) 5 (24%) 4 (19%)

  • Mild

 5 (24%) 2 (9%) 3 (14%)

  • Moderate

 6 (28%) 0 6 (28%)

  • Severe

 1 (5%) 0 1 (5%)
Time of liver pathology diagnosis in relation to IBD diagnosis, n (%)

  • Preceding

 3 (14%) 0 3 (14%)

  • Concomitant

 7 (33%) 0 7 (33%)

  • After

 11 (52%) 7 (33%) 4 (19%)
  • ○

    1–3 months

 3 (27%) 3 (43%) 0
  • ○

    4–6 months

 0 0 0
  • ○

    more than 6 months

 8 (73%) 4 (57%) 4 (100%)
Increase of ALT, n (%); median U/L (range) 17 (81%); 76 (44–805) 5 (24%); 76 (67–135) 12 (57%); 72 (44–805)

  • >1–2 × ULN

 8 (47%); 58 (44–70) 2 (12%); 68.5 (67–70) 6 (35%); 52 (44–68)

  • >2–3 × ULN

 3 (18%); 76 (76–86) 1 (6%); 76 2 (12%); 81 (76–86)

  • >3 × ULN

 6 (35%); 137 (112–805) 2 (12%); 130.5 (126–135) 4 (24%); 262 (112–805)
Increase of GGT, n (%); median IU/L (range) 11 (52%); 135 (49–418) 3 (14%); 60 (56–255) 8 (38%); 201.5 (49–418)

  • >1–2 × ULN

 5 (45%); 56 (49–61) 2 (67%); 58 (56–60) 3 (38%); 51 (49–61)

  • >2–3 × ULN

 0 0 0

  • >3 × ULN

 6 (55%); 274 (135–418) 1 (33%); 255 5 (62%); 280 (135–418)
Increase of ALT and GGT > 3 × ULN 4 (19%) 0 4 (19%)
Elevated direct bilirubin, n (%) 3 (14%) 2 (9%) 1 (5%)
Liver abnormalities in imaging studies, n (%) 12 (57%) 2 (9%) 10 (48%)

NA—nonapplicable, IBD—inflammatory bowel disease, CD—Crohn’s disease, UC—ulcerative colitis, PSC—primary sclerosing cholangitis, ASC—autoimmune sclerosing cholangitis, AIH—autoimmune hepatitis, NAFLD—non-alcoholic fatty liver disease, PCDAI—pediatric Crohn’s disease activity index, PUCAI—pediatric ulcerative colitis activity index, ALT—alanine transaminase, GGT—gamma-glutamyl transpeptidase, ULN—upper limit of normal.